Professor Shesternya Pavel Anatolyevich, MD

Internal Medicine Department One, Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Ministry of Health of Russia, Krasnoyarsk, Russia

1, Partisan Zheleznyak St., Krasnoyarsk 660022

shesternya75@mail.ru

Positions held in different years:

2005 to the present: Assistant Lecturer; Associate Professor; Professor, Department of Internal Medicine One, Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Ministry of Health ofRussia

2007 to the present: Head, Department of Clinical Trials, Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Ministry of Health ofRussia

2017 to the present: Principal Freelance Rheumatologist, Ministry of Health of the Krasnoyarsk Territory

Articles in international databases (2017-2019):

1. Шестерня ПА, Петрова ММ, Гриценко ОВ. Клинические аспекты применения этанерцепта в лечении ревматоидного артрита. Клиническая медицина. 2017;95(11):1007-12. [Shesternya PA, Petrova MM, Gritsenko OV. Clinical aspects of etanercept application in the treatment of rheumatoid arthritis. Klinicheskaya meditsina. 2017;95(11):1007-12. (In Russ.)].
2. Шестерня ПА, Петрова ММ, Васильева АО. Новые горизонты применения генно-инженерных биологических препаратов при беременности у больных ревматическими заболеваниями. Терапевтический архив. 2017;89(5):105-12. [Shesternya PA, Petrova MM, Vasil'eva AO. New horizons of application of genetically engineered biological drugs in pregnancy in patients with rheumatic diseases. Terapevticheskii arkhiv. 2017;89(5):105-12. (In Russ.)].
3. Васильева АО, Шестерня ПА, Петрова ММ. Ассоциация расстройств тревожно-депрессивного спектра и суставного синдрома у женщин. Научно-практическая ревматология. 2017;55(6):641-6. [Vasilyeva AO, Shesternya PA, Petrova MM. Association between anxiety-depressive spectrum disorders and joint disease in women. Rheumatology Science and Practice. 2017;55(6):641-646. (In Russ.)].
4. Yoo DH, Suh CH,ShimSC, et al. A multicenter randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2017 Mar;76(3):566-570. doi: 10.1136/annrheumdis-2016-209540. Epub 2016 Sep 13.
5. Park W, Suh CH,ShimSC, et al. Efficacy and safety of switching from innovator rituximab to biosimilar CT-P10 compared with continued treatment with CT-P10: results of a 56-weeks open-label study in patients with rheumatoid arthritis. BioDrugs. 2017 Aug;31(4):369-377. doi: 10.1007/s40259-017-0233-6.
6. Yoo DH, Suh SH, Shim SC, Jeka et al. Efficacy, safety and pharmacokinetics of up to two courses of the rituximab biosimilar CT-P10 versus innovator rituximab in patients wits rheumatoid arthritis: results up to week 72 of a phase I randomized controlled trial. BioDrugs. 2017 Aug;31(4):357-367. doi: 10.1007/s40259-017-0232-7.
7. Лила АМ, Мазуров ВИ, Зонова ЕВ и др. Сравнительная оценка долгосрочной эффективности и безопасности биоаналога инфликсимаба BCD-055 и референтного инфликсимаба у пациентов с анкилозирующим спондилитом: результаты международного многоцентрового рандомизированного двойного слепого клинического исследования III фазы ASART-2. Научно-практическая ревматология. 2018;56(3):293-301. [Lila AM, Mazurov VI, Zonova EV, et al. Comparative evaluation of the long-term efficacy and safety of the infliximab biosimilar bcd-055 and reference infliximab in patients with ankylosing spondylitis: results of the international multicenter randomized double-blind phase iii clinical study ASART-2. Rheumatology Science and Practice. 2018;56(3):293-301. (In Russ.)].
8. Park W, Bosic-Majstorovic L, Milakovic D, et al. Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial. MAbs. 2018 Aug/Sep;10(6):934-943. doi: 10.1080/19420862.2018.1487912. Epub 2018 Jul 16.
9. Коротаева ТВ, Корсакова ЮЛ, Логинова ЕЮ и др. Оптимизация диагностики, системы мониторинга и лечения псориатического артрита в реальной практике: общие принципы организации Общероссийского регистра пациентов с псориатическим артритом. Научно-практическая ревматология. 2019;57(4):407-414. [Korotaeva TV, Korsakova YL, Loginova EY, et al. Optimizing the diagnosis, a monitoring and treatment system for psoriatic arthritis in real practice: general principles for organizing an all-russian register of patients with psoriatic arthritis. Rheumatology Science and Practice. 2019;57(4):407-414. (In Russ.)].
10. Шестерня ПА, Прокопенко СВ, Можейко ЕЮ и др. Лекарственная энцефалопатия с нарушением когнитивных функций на фоне применения тоцилизумаба. Научно-практическая ревматология.  2019;57(4):482-485. [Shesternya PA, Prokopenko SV, Mozheiko EY, et al. Drug-induced encephalopathy with impaired cognitive functions during tocilizumab use. Rheumatology Science and Practice. 2019;57(4):482-485. (In Russ.)].
11. ShimSC, Božić-Majstorović L, Berrocal Kasay A, et al. Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial. Rheumatology (Oxford). 2019 Dec 1;58(12):2193-2202
12. Suh CH, Yoo DH, Kasay AB, et al. Long-term efficacy and safety of biosimilar CT-P10 versus innovator rituximab in rheumatoid arthritis: 48-week results from a randomized phase III trial. BioDrugs. 2019 Feb;33(1):79-91. doi: 10.1007/s40259-018-00331-4.